SLC5A2 and congestive heart failure: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have become a cornerstone in the management of chronic heart failure (CHF), showing significant cardiovascular benefits that are independent of glycaemic control.4, 5, 6